Overview

DZD9008 PK Study in Hepatic Impairment Subjects

Status:
Recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

This study will investigate the pharmacokinetics, safety, and tolerability of DZD9008 in subjects with hepatic impairment compared to subjects with normal hepatic function

Phase:

Phase 1

Details

Lead Sponsor:

Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Collaborator:

PPD Development, L.P.